Immunotherapy plus chemo shows promise against tough head and neck cancers
NCT ID NCT05522985
First seen Jan 16, 2026 · Last updated Apr 29, 2026 · Updated 14 times
Summary
This study tests whether adding an immunotherapy drug (treprizumab) to standard chemotherapy before surgery can improve outcomes for people with advanced head and neck cancer. About 122 participants will be randomly assigned to receive either the combination or chemotherapy alone. The main goal is to see if the combination leads to a higher rate of complete tumor disappearance after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China
Conditions
Explore the condition pages connected to this study.